Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24010757 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Xiwei Ji und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Pharmacology, Peking University First Hospital, Beijing 100034, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Breast Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
This study investigated the antitumor effects of foretinib on triple-negative breast cancer cells MDA-MB-231 xenograft tumors in vivo underlying phosphorylated mesenchymal to epithelial transition (p-MET)/ hepatocyte growth factor (HGF)-related mechanism, as well as its pharmacokinetic characteristics. The MDA-MB-231 human breast cancer cell line was used for in vitro experiments, and the tumor xenograft model was established for in vivo experiments. MDA-MB-231 xenograft mice received oral foretinib (15 or 50 mg/kg/day) or vehicle for 18 days. The xenograft tumors were collected. Protein expressions of p-MET and HGF were examined with Western blotting and immunohistochemical staining. The mRNA expression of MET was examined with real-time PCR. Blood samples were collected from the mice treated with foretinib under different doses of 2, 10, and 50 mg/kg, and the pharmacokinetic profiles of foretinib were evaluated. We found that foretinib treatment caused a significant inhibition in tumor growth in a dose-dependent manner, whereas the continuous administration did not result in weight loss in treated nude mice. In both MDA-MB-231 cells and xenograft tumors, foretinib suppressed the expression of p-MET and HGF. These findings reveal that the decrease of p-MET and HGF may play an important role in the anti-breast cancer properties of foretinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Pharmacology, Peking University First Hospital, Beijing 100034, China.
- Intensive Care Unit, Xiyuan Hospital of China Academy of Traditional Chinese Medicine, Beijing 100091, China.
- Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai 201203, China.
ORCID-Profile: Qingfeng He, Xiaoqiang Xiang, Yufei Shi, Xiao Zhu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ji, X., Meng, X., He, Q., Xiang, X., Shi, Y., & Zhu, X. (2023). Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24010757
Vancouver
Ji X, Meng X, He Q, Xiang X, Shi Y, Zhu X. Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24010757
BibTeX
@article{Ji2023,
author = {Ji, Xiwei and Meng, Xiangrui and He, Qingfeng and Xiang, Xiaoqiang and Shi, Yufei and Zhu, Xiao},
title = {Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24010757}
}
EUVIMED